First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1

ReachMD CME

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-metastatic-melanoma-after-adjuvant-anti-pd-1/24366/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.